Study links anemia drugs to fatal blood clots

11/11/2009 | U.S. News & World Report

Researchers found that cancer patients who received erythropoiesis-stimulating agents, such as Procrit and Aranesp, to prevent chemotherapy-related anemia were more likely to develop deep vein thrombosis or pulmonary embolism than those who did not receive the drugs. The results raise concerns regarding the approval process and postmarketing research conducted to ensure long-term safety of such drugs, the lead researcher said.

View Full Article in:

U.S. News & World Report

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT